- Home
- ALTO vs MGNX Comparison
ALTO vs MGNX Comparison
Compare ALTO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTO
- MGNX
- Stock Information
- Founded
- ALTO 2003
- MGNX 2000
- Country
- ALTO United States
- MGNX United States
- Employees
- ALTO N/A
- MGNX N/A
- Industry
- ALTO Major Chemicals
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ALTO Industrials
- MGNX Health Care
- Exchange
- ALTO Nasdaq
- MGNX Nasdaq
- Market Cap
- ALTO 90.6M
- MGNX 99.7M
- IPO Year
- ALTO N/A
- MGNX 2013
- Fundamental
- Price
- ALTO $1.06
- MGNX $1.86
- Analyst Decision
- ALTO Strong Buy
- MGNX Hold
- Analyst Count
- ALTO 1
- MGNX 6
- Target Price
- ALTO $5.50
- MGNX $3.20
- AVG Volume (30 Days)
- ALTO 247.9K
- MGNX 726.3K
- Earning Date
- ALTO 11-06-2025
- MGNX 11-04-2025
- Dividend Yield
- ALTO N/A
- MGNX N/A
- EPS Growth
- ALTO N/A
- MGNX N/A
- EPS
- ALTO N/A
- MGNX N/A
- Revenue
- ALTO $933,137,000.00
- MGNX $165,495,000.00
- Revenue This Year
- ALTO N/A
- MGNX N/A
- Revenue Next Year
- ALTO $7.53
- MGNX N/A
- P/E Ratio
- ALTO N/A
- MGNX N/A
- Revenue Growth
- ALTO N/A
- MGNX 303.47
- 52 Week Low
- ALTO $0.76
- MGNX $0.99
- 52 Week High
- ALTO $2.05
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- ALTO 45.48
- MGNX 55.15
- Support Level
- ALTO $1.05
- MGNX $1.82
- Resistance Level
- ALTO $1.12
- MGNX $2.15
- Average True Range (ATR)
- ALTO 0.05
- MGNX 0.13
- MACD
- ALTO -0.01
- MGNX 0.01
- Stochastic Oscillator
- ALTO 6.25
- MGNX 49.15
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.